+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gastroparesis Drugs Global Market Report 2024

  • PDF Icon

    Report

  • 175 Pages
  • July 2024
  • Region: Global
  • The Business Research Company
  • ID: 5986828
The gastroparesis drugs market size has grown strongly in recent years. It will grow from $5.09 billion in 2023 to $5.39 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to gastrointestinal motility research, side effects of existing treatments, clinical need, regulatory support, and patient advocacy.

The gastroparesis drugs market size is expected to see strong growth in the next few years. It will grow to $6.81 billion in 2028 at a compound annual growth rate (CAGR) of 6%. The anticipated expansion in the forecast period is linked to the heightened occurrence of diabetes, the aging demographic, heightened awareness and diagnosis rates, augmented healthcare spending, and support from both governmental and private sectors. Key trends anticipated during this period encompass progressions in gastroenterology, enhancements in diagnostic methodologies, technological breakthroughs, increased research funding, and collaborative research initiatives.

The surge in diabetes prevalence is anticipated to drive the progression of the gastroparesis drugs market in the foreseeable future. Diabetes, characterized by elevated blood sugar levels due to insufficient insulin production or its ineffective utilization, persists as a significant health concern. Factors contributing to the escalating diabetes rates include sedentary lifestyles, poor dietary habits, genetic predisposition, urbanization, and aging populations, alongside limited healthcare access and escalating global obesity rates. Gastroparesis drugs are commonly prescribed to diabetic patients to mitigate symptoms such as nausea, vomiting, and delayed stomach emptying, common complications arising from impaired gastrointestinal motility associated with diabetes. These medications aim to ameliorate gastric function and enhance the quality of life for individuals grappling with diabetes-related gastroparesis. For instance, as reported by the International Diabetes Federation in 2021, the projected number of individuals afflicted by diabetes is anticipated to soar to 643 million by 2030 and 783 million by 2045. Hence, the escalating prevalence of diabetes underscores the expansion of the gastroparesis drugs market.

Major players in the gastroparesis drugs sector are directing their efforts towards introducing innovative medications, such as the Gimoti (metoclopramide) nasal spray, to enhance their market competitiveness. Gimoti (metoclopramide) nasal spray is a pharmaceutical designed to alleviate symptoms of gastroparesis in adults, fostering stomach emptying by bolstering gastrointestinal motility. By circumventing the gastrointestinal tract, it is absorbed directly into the bloodstream via the nasal mucosa. For example, in April 2022, Evoke Pharma Inc., a pharmaceutical company based in the United States, disclosed that the U.S. Food and Drug Administration (FDA) had granted GIMOTI (metoclopramide) nasal spray new drug product exclusivity. This exclusivity affords Evoke exclusive marketing privileges for three years following the initial approval date, as per the Hatch-Waxman Act, shielding the product from generic competition.

In June 2022, Eagle Pharmaceuticals Inc., a pharmaceutical firm headquartered in the United States, completed the acquisition of Acacia Pharma Group plc for $102 million (€94.7 million). Through this acquisition, Eagle Pharmaceuticals intends to broaden its range of offerings by integrating Acacia's FDA-approved hospital products, BARHEMSYS and BYFAVO, which cater to unmet clinical demands in acute care environments. Acacia Pharma Group plc, based in the United Kingdom, specializes in providing antiemetic medications utilized in gastroparesis treatment.

Major companies operating in the gastroparesis drugs market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Inc., Teva Pharmaceutical Inc., Otsuka Pharmaceutical Co. Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Evoke Pharma Inc., Cadila Pharmaceuticals, Cipla Ltd., Neurogastrx Inc., Ipca Laboratories Ltd., ANI Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc, Rhythm Pharmaceuticals Inc., Processa Pharmaceuticals Inc., Aclipse Therapeutics LLC, ETX Pharma Inc.

North America was the largest region in the gastroparesis drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastroparesis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gastroparesis drugs are medications utilized to handle and address gastroparesis, a condition characterized by delayed emptying of the stomach, leading to symptoms such as nausea, vomiting, and abdominal discomfort. Typically, these medications consist of prokinetics to enhance stomach motility, antiemetics to regulate nausea and vomiting, and drugs to alleviate pain and other associated symptoms.

The primary categories of gastroparesis drugs consist of over-the-counter (OTC) medications and prescription drugs. Over-the-counter (OTC) drugs are those available for purchase without a prescription from a healthcare provider. These medications are utilized for treating various forms of gastroparesis, including diabetic gastroparesis, post-surgical gastroparesis, idiopathic gastroparesis, among others, and are administered through various routes such as oral ingestion, injection, and others. They encompass various types of drugs such as prokinetic agents, antiemetics, proton pump inhibitors, among others, which are distributed through hospitals, pharmacies, clinics, and online platforms.

The gastroparesis drugs market research report is one of a series of new reports that provides gastroparesis drugs market statistics, including gastroparesis drugs industry global market size, regional shares, competitors with a gastroparesis drugs market share, detailed gastroparesis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gastroparesis drugs industry. This gastroparesis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastroparesis drugs market consists of sales of ondansetron, metoclopramide, amitriptyline, and erythromycin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Gastroparesis Drugs Market Characteristics3. Gastroparesis Drugs Market Trends and Strategies
4. Gastroparesis Drugs Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global Gastroparesis Drugs Market Size and Growth
5.1. Global Gastroparesis Drugs Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global Gastroparesis Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Gastroparesis Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)
6. Gastroparesis Drugs Market Segmentation
6.1. Global Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Over-the-Counter (OTC) Drugs
  • Prescription Drugs
6.2. Global Gastroparesis Drugs Market, Segmentation by Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Diabetic Gastroparesis
  • Post-Surgical Gastroparesis
  • Idiopathic Gastroparesis
  • Other Disease Types
6.3. Global Gastroparesis Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Injectables
  • Other Routes of Administration
6.4. Global Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Prokinetic Agents
  • Antiemetic Drugs
  • Proton Pump Inhibitors
  • Other Drug Classes
6.5. Global Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Pharmacies
  • Clinics
  • E-commerce
7. Gastroparesis Drugs Market Regional and Country Analysis
7.1. Global Gastroparesis Drugs Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Gastroparesis Drugs Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Gastroparesis Drugs Market
8.1. Asia-Pacific Gastroparesis Drugs Market Overview
(Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies)
8.2. Asia-Pacific Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Gastroparesis Drugs Market
9.1. China Gastroparesis Drugs Market Overview
9.2. China Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Gastroparesis Drugs Market
10.1. India Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Gastroparesis Drugs Market
11.1. Japan Gastroparesis Drugs Market Overview
11.2. Japan Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Gastroparesis Drugs Market
12.1. Australia Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Gastroparesis Drugs Market
13.1. Indonesia Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Gastroparesis Drugs Market
14.1. South Korea Gastroparesis Drugs Market Overview
14.2. South Korea Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Gastroparesis Drugs Market
15.1. Western Europe Gastroparesis Drugs Market Overview
15.2. Western Europe Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Gastroparesis Drugs Market
16.1. UK Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Gastroparesis Drugs Market
17.1. Germany Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Gastroparesis Drugs Market
18.1. France Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Gastroparesis Drugs Market
19.1. Italy Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Gastroparesis Drugs Market
20.1. Spain Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Gastroparesis Drugs Market
21.1. Eastern Europe Gastroparesis Drugs Market Overview
21.2. Eastern Europe Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Gastroparesis Drugs Market
22.1. Russia Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Gastroparesis Drugs Market
23.1. North America Gastroparesis Drugs Market Overview
23.2. North America Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Gastroparesis Drugs Market
24.1. USA Gastroparesis Drugs Market Overview
24.2. USA Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Gastroparesis Drugs Market
25.1. Canada Gastroparesis Drugs Market Overview
25.2. Canada Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Gastroparesis Drugs Market
26.1. South America Gastroparesis Drugs Market Overview
26.2. South America Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Gastroparesis Drugs Market
27.1. Brazil Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Gastroparesis Drugs Market
28.1. Middle East Gastroparesis Drugs Market Overview
28.2. Middle East Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Gastroparesis Drugs Market
29.1. Africa Gastroparesis Drugs Market Overview
29.2. Africa Gastroparesis Drugs Market, Segmentation by Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Gastroparesis Drugs Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Gastroparesis Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Gastroparesis Drugs Market Competitive Landscape and Company Profiles
30.1. Gastroparesis Drugs Market Competitive Landscape
30.2. Gastroparesis Drugs Market Company Profiles
30.2.1. Pfizer Inc.
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. AbbVie Inc.
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Bayer AG
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Sanofi SA.
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. AstraZeneca plc
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Gastroparesis Drugs Market Other Major and Innovative Companies
31.1. Abbott Laboratories
31.2. GSK plc
31.3. Takeda Pharmaceutical Inc.
31.4. Teva Pharmaceutical Inc.
31.5. Otsuka Pharmaceutical Co. Ltd.
31.6. Bausch Health Companies Inc.
31.7. Eisai Co. Ltd.
31.8. Evoke Pharma Inc.
31.9. Cadila Pharmaceuticals
31.10. Cipla Ltd.
31.11. Neurogastrx Inc.
31.12. Ipca Laboratories Ltd.
31.13. ANI Pharmaceuticals Inc.
31.14. Salix Pharmaceuticals Inc.
31.15. Vanda Pharmaceuticals Inc.
32. Global Gastroparesis Drugs Market Competitive Benchmarking33. Global Gastroparesis Drugs Market Competitive Dashboard34. Key Mergers and Acquisitions in the Gastroparesis Drugs Market
35. Gastroparesis Drugs Market Future Outlook and Potential Analysis
35.1 Gastroparesis Drugs Market in 2028 - Countries Offering Most New Opportunities
35.2 Gastroparesis Drugs Market in 2028 - Segments Offering Most New Opportunities
35.3 Gastroparesis Drugs Market in 2028 - Growth Strategies
35.3.1 Market Trend-based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Gastroparesis Drugs Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastroparesis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for gastroparesis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastroparesis drugs market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • The continued but declining impact of COVID-19 on supply chains and consumption patterns.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Drug Type: Over-the-counter (OTC) Drugs; Prescription Drugs
2) By Drug Class: Prokinetic Agents; Antiemetic Drugs; Proton Pump Inhibitors; Other Drug Classes
3) By Disease Type: Diabetic Gastroparesis; Post-Surgical Gastroparesis; Idiopathic Gastroparesis; Other Disease Types
4) By Route Of Administration: Oral; Injectables; Other Routes Of Administration
5) By Distribution Channel: Hospitals; Pharmacies; Clinics; E-commerce

Key Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Bayer AG; Sanofi SA.; AstraZeneca plc

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Pfizer Inc.
  • AbbVie Inc.
  • Bayer AG
  • Sanofi SA.
  • AstraZeneca plc
  • Abbott Laboratories
  • GSK plc
  • Takeda Pharmaceutical Inc.
  • Teva Pharmaceutical Inc.
  • Otsuka Pharmaceutical Co. Ltd.
  • Bausch Health Companies Inc.
  • Eisai Co. Ltd.
  • Evoke Pharma Inc.
  • Cadila Pharmaceuticals
  • Cipla Ltd.
  • Neurogastrx Inc.
  • Ipca Laboratories Ltd.
  • ANI Pharmaceuticals Inc.
  • Salix Pharmaceuticals Inc.
  • Vanda Pharmaceuticals Inc.
  • Theravance Biopharma Inc
  • Rhythm Pharmaceuticals Inc.
  • Processa Pharmaceuticals Inc.
  • Aclipse Therapeutics LLC
  • ETX Pharma Inc.

Methodology

Loading
LOADING...

Table Information